Mechanistic Target of Rapamycin Complex 1 Expands Th17 and IL-4+ CD4-CD8-Double-Negative T Cells and Contracts Regulatory T Cells in Systemic Lupus Erythematosus

被引:125
|
作者
Kato, Hiroshi
Perl, Andras
机构
[1] SUNY Upstate Med Univ, Coll Med, Dept Med, Div Rheumatol, Syracuse, NY 13210 USA
[2] SUNY Upstate Med Univ, Coll Med, Dept Microbiol & Immunol, Div Rheumatol, Syracuse, NY 13210 USA
[3] SUNY Upstate Med Univ, Coll Med, Dept Biochem & Mol Biol, Div Rheumatol, Syracuse, NY 13210 USA
基金
美国国家卫生研究院;
关键词
ROR-GAMMA-T; MAMMALIAN TARGET; DISEASE-ACTIVITY; DECREASED PRODUCTION; INTERFERON-GAMMA; HELPER-CELLS; MTOR KINASE; TGF-BETA; IN-VIVO; DIFFERENTIATION;
D O I
10.4049/jimmunol.1301859
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mechanistic target of rapamycin (mTOR) is activated in CD4-CD8-double-negative (DN) T cells and its blockade is therapeutic in systemic lupus erythematosus (SLE) patients. Murine studies showed the involvement of mTOR complex 1 (mTORC1) and 2 (mTORC2) in the differentiation of Th1/Th17 cells and Th2 cells, respectively. In this study, we investigated the roles of mTORC1 and mTORC2 in T cell lineage development in SLE and matched healthy control (HC) subjects. mTORC1 activity was increased, whereas mTORC2 was reduced, as assessed by phosphorylation of their substrates phosphorylated S6 kinase 1 or phosphorylated S6 ribosomal protein and phosphorylated Akt, respectively. Rapamycin inhibited mTORC1 and enhanced mTORC2. IL-4 expression was increased in freshly isolated CD8(+) lupus T cells (SLE: 8.09 +/- 1.93%, HC: 3.61 +/- 0.49%; p = 0.01). DN T cells had greater IL-4 expression than CD4(+) or CD8(+) T cells of SLE patients after 3-d in vitro stimulation, which was suppressed by rapamycin (control: 9.26 +/- 1.48%, rapamycin: 5.03 +/- 0.66%; p < 0.001). GATA-3 expression was increased in CD8(+) lupus T cells (p < 0.01) and was insensitive to rapamycin treatment. IFN-gamma expression was reduced in all lupus T cell subsets (p = 1.0 x 10(-5)) and also resisted rapamycin. IL-17 expression was increased in CD4(+) lupus T cells (SLE: 3.62 +/- 0.66%, HC: 2.29 +/- 0.27%; p = 0.019), which was suppressed by rapamycin (control: 3.91 +/- 0.79%, rapamycin: 2.22 +/- 0.60%; p < 0.001). Frequency of regulatory T cells (Tregs) was reduced in SLE (SLE: 1.83 +/- 0.25%, HC: 2.97 +/- 0.27%; p = 0.0012). Rapamycin inhibited mTORC1 in Tregs and promoted their expansion. Neutralization of IL-17, but not IL-4, also expanded Tregs in SLE and HC subjects. These results indicate that mTORC1 expands IL-4(+) DN T and Th17 cells, and contracts Tregs in SLE. The Journal of Immunology, 2014, 192: 4134-4144.
引用
收藏
页码:4134 / 4144
页数:11
相关论文
共 50 条
  • [1] Th17 cells and CD4+ multifunctional T cells in patients with systemic lupus erythematosus
    Pereira Araujo, Julio Antonio
    Mesquita, Danilo, Jr.
    Cruvinel, Wilson de Melo
    Salmazi, Karina Inacio
    Kallas, Esper Georges
    Coelho Andrade, Luis Eduardo
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2016, 56 (01) : 28 - 36
  • [2] Imbalance between Th17 and regulatory T-cells in systemic lupus erythematosus
    Kleczynska, Weronika
    Jakiela, Bogdan
    Plutecka, Hanna
    Milewski, Mamert
    Sanak, Marek
    Musial, Jacek
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2011, 49 (04) : 646 - 653
  • [3] Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus
    Lai, Zhi-Wei
    Borsuk, Rebecca
    Shadakshari, Ashwini
    Yu, Jianghong
    Dawood, Maha
    Garcia, Ricardo
    Francis, Lisa
    Tily, Hajra
    Bartos, Adam
    Faraone, Stephen V.
    Phillips, Paul
    Perl, Andras
    JOURNAL OF IMMUNOLOGY, 2013, 191 (05) : 2236 - 2246
  • [4] Increased IL-17 and IL-21 producing TCRαβ+CD4-CD8- T cells in Chinese systemic lupus erythematosus patients
    Wang, H-X
    Chu, S.
    Li, J.
    Lai, W-N
    Wang, H-X
    Wu, X-J
    Kang, X.
    Qiu, Y-R
    LUPUS, 2014, 23 (07) : 643 - 654
  • [5] Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus
    Yang, Ji
    Yang, Xue
    Zou, Hejian
    Chu, Yiwei
    Li, Ming
    RHEUMATOLOGY, 2011, 50 (08) : 1366 - 1372
  • [6] Cutting Edge: Leptin-Induced RORγt Expression in CD4+ T Cells Promotes Th17 Responses in Systemic Lupus Erythematosus
    Yu, Yiyun
    Liu, Yaoyang
    Shi, Fu-Dong
    Zou, Hejian
    Matarese, Giuseppe
    La Cava, Antonio
    JOURNAL OF IMMUNOLOGY, 2013, 190 (07) : 3054 - 3058
  • [7] Balance between Regulatory T and Th17 Cells in Systemic Lupus Erythematosus: The Old and the New
    Alunno, Alessia
    Bartoloni, Elena
    Bistoni, Onelia
    Nocentini, Giuseppe
    Ronchetti, Simona
    Caterbi, Sara
    Valentini, Valentina
    Riccardi, Carlo
    Gerli, Roberto
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [8] Advances on Non-CD4+Foxp3+T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation
    Ligocki, Ann J.
    Niederkorn, Jerry Y.
    TRANSPLANTATION, 2015, 99 (08) : 1553 - 1559
  • [9] Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients
    Masuda, Masayuki
    Matsumoto, Moe
    Tanaka, Sachiko
    Nakajima, Kanako
    Yamada, Nao
    Ido, Nobuhiro
    Ohtsuka, Takao
    Nishida, Masashi
    Hirano, Toshihiko
    Utsumi, Hiroya
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 225 (1-2) : 123 - 131
  • [10] IL-22+CD4+ T-cells in patients with active systemic lupus erythematosus
    Zhao, Ling
    Jiang, Zhenyu
    Jiang, Yanfang
    Ma, Ning
    Wang, Kai
    Zhang, Yandong
    Feng, Li
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 238 (02) : 193 - 199